Key result
Novel Lp(a)-targeted therapies including antisense oligonucleotides and siRNAs reduce Lp(a) levels by up to 90%, with ongoing phase III trials evaluating their impact on cardiovascular outcomes.
Answers are grounded in this paper and cite their sources.
This review synthesizes the pathophysiological role of Lp(a) across vascular territories and highlights emerging RNA-based and gene-editing therapies capable of reducing Lp(a) by up to 90%, pending phase III cardiovascular outcome trial results.
Lipoprotein(a) (Lp(a)) is an elusive yet powerful cardiovascular risk factor, largely independent of LDL cholesterol. Elevated Lp(a) increases the risk of coronary artery disease, stroke, peripheral arterial disease, calcific aortic valve disease, heart failure, and abdominal aortic aneurysm. The challenge is that conventional lipid-lowering therapies have minimal impact on Lp(a), leaving patients with substantial residual risk. While observational and genetic studies generally support Lp(a) as a driver of cardiovascular events, results are not entirely consistent, and risk may differ between primary and secondary prevention. Novel therapies—including antisense oligonucleotides, siRNA therapeutics, CETP inhibitors, and experimental gene-editing approaches—show promising potential, reducing Lp(a) levels by up to 90%. Ongoing phase III trials will clarify whether these reductions translate into meaningful decreases in cardiovascular morbidity and mortality. This review critically examines the current evidence, highlights gaps in knowledge, and discusses emerging therapeutic strategies, emphasizing the need for individualized risk assessment. Lp(a) may soon shift from a “silent threat” to a precise, actionable target in cardiovascular prevention.
No takes yet. Share an insight, caveat, or question.
Miszczak et al. (2026) conducted a review in Elevated lipoprotein(a) and atherosclerotic cardiovascular disease. Emerging Lp(a)-lowering therapies (antisense oligonucleotides, siRNA therapeutics, CETP inhibitors, gene-editing approaches) was evaluated on Lp(a) concentration reduction and cardiovascular morbidity and mortality. Novel Lp(a)-targeted therapies including antisense oligonucleotides and siRNAs reduce Lp(a) levels by up to 90%, with ongoing phase III trials evaluating their impact on cardiovascular outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: